Publications by authors named "Jonathan Uy"

Claim this Profile
T
The Effectiveness of Guselkumab by BMI Category Among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy

Adv Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Guselkumab Therapy among Patients with Plaque Psoriasis with Baseline IGA Score ≥ 2 in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy

Dermatol Ther (Heidelb)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Effectiveness of 9-12 Months of Guselkumab Therapy among Patients with Moderate-to-Severe Plaque Psoriasis in the CorEvitas Psoriasis Registry.
April W Armstrong, Timothy Fitzgerald, Robert R McLean, Amanda Teeple, Jonathan P Uy

Dermatol Ther (Heidelb)· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.
Jessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, Soumya D Chakravarty, Timothy Fitzgerald, Jonathan Uy

Dermatol Ther (Heidelb)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcomes of patients with peripheral artery disease undergoing endovascular revascularization: A community hospital perspective.
S Michael Gharacholou, Zhuo Li, Jonathan J Uy, Lee H Eckstein, Carolyn R Flock

Vascular· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
Robert Bissonnette, Alice B Gottlieb, Richard G Langley, Craig L Leonardi, Kim A Papp, Jonathan Uy

Drug Saf· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Li Zhu, Roger J Brüggemann, Jonathan Uy, Angela Colbers, Matthew W Hruska

J Clin Pharmacol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians.
Hillel Cohen, Donna Beydoun, David Chien, Tracy Lessor, Dorothy McCabe, Jonathan Uy

Adv Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in biomarkers in HIV-1-infected treatment-naive patients treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy.
Graeme Moyle, Helene Hardy, Jonathan Uy, Neelanjana Ray, Maria Jesus Jimenez-Exposito

Antivir Ther· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study.
Wayne J G Hellstrom, Jed Kaminetsky, Laurence H Belkoff, Irwin Goldstein, James P Tursi, Jonathan Uy

J Urol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy.
Stephen S Johnston, Timothy Juday, Stephen Esker, Derek Espindle, Bong-Chul Chu, Jonathan Uy

Value Health· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study.
Sonia Napravnik, Joseph J Eron, Timothy R Sterling, Timothy Juday, Jonathan Uy

AIDS Res Hum Retroviruses· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
Thomas B Campbell, Laura M Smeaton, N Kumarasamy, Timothy Flanigan, Karin L Klingman, Jonathan Uy

PLoS Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Max Lataillade, Jennifer Chiarella, Rong Yang, Michelle DeGrosky, Jonathan Uy

PLoS One· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.
Stephen Esker, Jessica Albano, Jonathan Uy, Dilek Arikan, Maria Jesus Jimenez-Exposito

AIDS Patient Care STDS· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
Cheryl McDonald, Jonathan Uy, Wenhua Hu, Victoria Wirtz, Salome Juethner

AIDS Patient Care STDS· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Jonathan Uy, Rong Yang, Victoria Wirtz, Louise Sheppard, Awny Farajallah

AIDS Care· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Michael S Broder, Eunice Y Chang, Tanya G K Bentley, Timothy Juday, Jonathan Uy

J Med Econ· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Kathleen E Squires, Margaret Johnson, Rong Yang, Jonathan Uy, Louise Sheppard

J Antimicrob Chemother· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study.
Max Lataillade, Jennifer Chiarella, Rong Yang, Steven Schnittman, Victoria Wirtz, Jonathan Uy

PLoS One· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure.
Jonathan Uy, Carl Armon, Kate Buchacz, Kathy Wood, John T Brooks

J Acquir Immune Defic Syndr· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
Michael J Kozal, Katherine Huppler Hullsiek, Rodger D Macarthur, Mary van den Berg-Wolf, Grace Peng, Jonathan Uy

HIV Clin Trials· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
Jonathan Uy, John T Brooks, Rose Baker, Mark Hoffman, Anne Moorman

Antivir Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy.
Richard M Novak, Li Chen, Rodger D MacArthur, John D Baxter, Kathy Huppler Hullsiek, Jonathan Uy

Clin Infect Dis· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving forward in HIV medicine.
Jonathan Uy

Posit Aware· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis